NCT06861452View on ClinicalTrials.gov

Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 25, 2025

Primary Completion Date

July 29, 2026

Study Completion Date

January 29, 2027

Conditions
Locally Advanced Pancreatic Adenocarcinoma
Interventions
DRUG

RR001

RR001, a cell-based gene therapy administered following administration of chemotherapy (Nab-PTX 125 mg/mq and GEM 1000 mg/mq)

Trial Locations (1)

41124

RECRUITING

Azienda Ospedaliero-Universitaria (AOU) Policlinico di Modena, Modena

All Listed Sponsors
lead

EIR Biotherapies s.r.l.

INDUSTRY

NCT06861452 - Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma | Biotech Hunter | Biotech Hunter